Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer by Li, Chengwen et al.
original article© The American Society of Gene & Cell Therapy
A major hindrance in gene therapy trials with adeno-
associated virus (AAV) vectors is the presence of neutral-
izing antibodies (NAbs) that inhibit AAV transduction. In 
this study, we used directed evolution techniques in vitro 
and in mouse muscle to select novel NAb escape AAV 
chimeric capsid mutants in the presence of individual 
patient serum. AAV mutants isolated in vitro escaped 
broad patient-specific NAb activity but had poor trans-
duction ability in vivo. AAV mutants isolated in vivo had 
enhanced NAb evasion from cognate serum and had 
high muscle transduction ability. More importantly, 
structural modeling identified a 100 amino acid motif 
from AAV6 in variable region (VR) III that confers this 
enhanced muscle tropism. In addition, a predominantly 
AAV8 capsid beta barrel template with a specific prefer-
ence for AAV1/AAV9 in VR VII located at threefold sym-
metry axis facilitates NAb escape. Our data strongly 
support that chimeric AAV capsids composed of modu-
lar and nonoverlapping domains from various serotypes 
are capable of evading patient-specific NAbs and have 
enhanced muscle transduction.
Received 2 February 2015; accepted 18 July 2015; advance online  
publication 25 August 2015. doi:10.1038/mt.2015.134
INTRODUCTION
Adeno-associated virus (AAV) vectors have been explored exten-
sively in numerous preclinical studies and a number of these stud-
ies are currently translating into encouraging phase 1, 2, and 3 
clinical trials.1–5 While AAV gene therapy continues to yield clini-
cal results supportive of the hope for eventual treatment of many 
diseases, the presence of patient neutralizing antibodies (NAbs) 
remains a challenge. NAb-mediated elimination of AAV vectors 
has become a rate-limiting step in advancing the field and a deter-
minant for repeat administration of AAV gene transfer.1,2,6 The 
fact that more than 90% of the population has been exposed to 
natural AAV2 infection, and half of those infected carry NAbs in 
their blood,7–17 highlights the significance of this problem.
Although AAV2 vectors are used in the majority of clinical 
trials,2,18,19 other serotypes, such as AAV1, 8, or customized vectors 
such as AAV2.5 are being explored.1,6,20 In an early phase 1 clinical 
trial with hemophilia B patients using an AAV2 vector encoding 
the factor IX (F.IX) transgene, ~10% of normal F.IX levels were 
achieved in one patient who lacked NAbs and no detectable F.IX 
was observed in a second patient with preexisting AAV2 NAbs.2 
More recently, we performed a phase 1 clinical trial in six patients 
with Duchenne muscular dystrophy (DMD) using the chimeric 
AAV2.5 vector encoding a mini-dystrophin transgene for muscle 
delivery. Before intramuscular (i.m.) injection, no AAV2 NAbs 
were found in three patients, low NAb titers were detected in one 
patient, and high NAb titers were detected in the remaining two 
patients. After injection, vector genomes were only detected in 
muscle biopsies from patients with no or low titers of NAbs.6 This 
observation suggests that NAbs inhibit AAV transduction follow-
ing direct i.m. injection.
Several approaches to overcome AAV NAbs include: plasma-
pheresis,21 reduction of NAb production with B-cell depletion,22 
use of empty AAV capsid decoys,23 alternative AAV serotypes 
that are naturally resistant to NAbs,9,24–27 selection of NAb escape 
mutants from an error-prone PCR library,28–30 site-directed modi-
fication of AAV capsid proteins,31 and AAV capsid-associated 
polymers that prevent NAb recognition.32–34 Based on kinetic 
analysis of the NAbs in our phase 1 clinical trial with hemophilia 
patients, NAb cross-reactivity was suggested as a primary mecha-
nism of neutralization of unrelated AAV serotypes.17 This observa-
tion was confirmed in results from our DMD phase 1 clinical trial. 
After i.m. injection of chimeric AAV2.5, all three patients initially 
lacking NAbs had AAV2 NAb titers at 1:100 (ref. 6). They also dis-
played differential inhibition to various AAV serotypes. Regarding 
the AAV capsid modification strategies to develop AAV mutants 
for NAb evasion, Maheshri et al.30 used an AAV2 library derived 
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from error prone PCR to isolate AAV NAb escape mutants in the 
presence of rabbit anti-AAV2 sera in vitro. Other studies, includ-
ing ours, have selected mutants with high tissue tropism using an 
AAV library from DNA shuffling of different serotypes; however, 
NAb evasion ability was only tested postselection in cell lines or in 
the presence of human intravenous immunglobin.35–37 In the cur-
rent study, we isolated AAV NAb escape mutants in the presence 
of individual patient serum from our DMD clinical trial using 
AAV directed evolution in vitro. Most importantly, we also per-
formed the selection of AAV mutants with NAb evasion in vivo to 
determine whether the mutants isolated from one patient’s serum 
are able to escape NAb activity from other sera and retain high 
tissue transduction. In HEK293 cells, AAV mutants selected from 
individual patient serum escaped NAb activity in sera from all 
subjects; however, all in vitro selected mutants were compromised 
in transducing target tissue in vivo. Importantly, we also selected 
AAV mutants with NAb evasion in vivo in BALB/c mouse muscle 
to determine whether the mutants isolated from one patient’s 
serum escaped NAb activity from other patient sera. The in vivo 
selection resulted in several capsid mutants recovered from skel-
etal muscle that not only escaped NAbs but also displayed high 
muscle transduction efficiency compared to most naturally occur-
ring AAV serotypes. To explore the capsid protein amino acid 
(aa) sequence required for NAb evasion and enhanced tropism, 
we conducted sequence alignment and structural analysis stud-
ies. Phylogenetic analysis and structural modeling of several of 
the selected mutants helped to identify AAV capsid motifs that 
can be further engineered to modulate NAb evasion while retain-
ing muscle tropism. This approach of generating personalized, 
patient-specific NAb AAV escape mutants represents a paradigm 
shift in steps required when exploiting AAV directed evolution to 
overcome immune limitations currently impacting gene transfer 
studies.
RESULTS
Characterization of AAV NAb escaping mutants 
isolated from HEK293 cells
In our phase 1 DMD clinical trial, six patients were treated via 
i.m. injection with a chimeric AAV2.5 encoding the mini-dystro-
phin transgene.6 Prior to vector administration, three patients had 
no AAV2 NAbs; however, sera collected 100 days posttreatment 
showed that AAV2 NAb titers increased to 1:1006. To select AAV 
NAb escape mutants, undiluted sera from these patients were 
combined with an AAV capsid shuffled library35,38 and applied 
to HEK293 cells in the presence of adenovirus (Ad). Forty-eight 
hours posttreatment, cell lysates containing the NAb escape 
mutants were again used to infect HEK293 cells in the presence 
of Ad for a second cycle of AAV amplification. After four rounds 
of amplification, NAb AAV mutants were isolated and sequenced. 
Nine, 8, and 12 mutants were isolated from patient sera 1, 2, 
and 3, respectively (Supplementary Figures S1). Most mutants 
from sera 1 and 2 contained a chimeric VP3 of AAV8 and AAV9 
(Table 1 and Supplementary Figure S1A,B). Eleven mutants iso-
lated from serum 3 contained the VP3 C-terminal from AAV8 
(Table 1 and Supplementary Figure S1C), and nine of them 
had the VP3-N-terminal of AAV1. In addition to capsid com-
position from different serotype of AAV, all mutants contained 
at least one point mutation. Most mutants produced comparable 
virus yields to AAV2, but lower titers were produced by mutants 
AAV001-12 and 15, AAV002-9, and AAV003-19 (Table 1). The 
AAV001-12 and 15 mutants have proline residues, L636P and 
N737P, respectively, close to VP interfaces, and the G640E muta-
tion in AAV002-9 is in a buried position inside the capsid likely to 
cause steric hindrance that may prevent viral capsid assembly. For 
AAV003-19 the T233Q residue is located in a β-strand inside the 
capsid. Thus, while the mechanism(s) behind a reduced or lack of 
virus production is unclear, it is likely that the point mutations in 
these constructs changed the VP structure, although individual 
AAV VP subunit can be formed, it is possible that the mutations 
result in insufficient AAV virion assembly from 60 VP subunits.
After identification and virus production in HEK293 cells, 
recombinant mutants packaging firefly luciferase transgene 
(luc) were tested for their ability to transduce HEK293 cells. The 
mutants possessed different transduction efficiency as compared 
with AAV2 (Table 1). Lower transduction was demonstrated for 
the mutants with the exception of mutant AAV001-14, which had 
similar transduction ability to AAV2.
NAb escaping ability of the mutants isolated in 
HEK293 cells
To investigate the capacity of mutants recovered from HEK293 
cells to escape NAbs from individual patient serum, we incubated 
mutants with undiluted serum at 4 °C for 2 hours. The unbound 
virus transduction was determined by adding the AAV mutant/
serum mixture to HEK293 cells. For escape mutants from serum 
1, all tested, with the exception of AAV001-7, exhibited transduc-
tion >50% of control without serum, especially mutants AAV001-
1, 4, and 5 which showed >80% transduction (Table 1 and 
Supplementary Figure S2). This may be because the N-terminus 
of AAV001-7 VP3 was derived from AAV1, and AAV1 transduc-
tion was inhibited by serum 1. In contrast, the other eight mutants’ 
VP3 was derived from AAV8 and 9, and AAV8 and 9 transduction 
was not inhibited to the same extent as was AAV1.
Among the escape mutants from serum 2, a diverse capsid 
composition was observed. Based on NAb escape analysis, mutants 
AAV002-9, 14, and 15 were resistant to serum 2, whereas the other 
five mutants were strongly inhibited (Table 1 and Supplementary 
Figure S2). Among the inhibited mutants, AAV002-16 was derived 
entirely from the AAV2 capsid but contained two mutations, S292L 
and K556E. It is interesting to note that serum 2 also inhibited trans-
duction from mutants AAV002-1 and 3, composed of an AAV1 VP1 
N-terminus (VP1u) and AAV8 and 9 VP3, while wild-type (wt) 
AAV8 and 9 escape the NAb activity of serum 2. This suggests the 
involvement of the VP1u in antibody recognition. Also, although 
serum 2 completely suppressed AAV2 transduction and partially 
inhibited AAV1 transduction, mutant AAV002-14, a chimera of 
AAV1 and 2, transduced HEK293 cells efficiently in the presence of 
serum 2. This is likely due to the presence of sequence variation at or 
close to antigenic regions of AAV1 and AAV2.31,39 In the presence of 
serum 3, transgene expression was decreased for AAV1, 2, 4, 8, and 9 
as well as chimeric AAV2.5. Among the 12 mutants, AAV003-7 and 
19 were able to escape the NAb activity to induce transgene expres-
sion >50% of control (Table 1 and Supplementary Figure S2). The 
other isolated mutants could not escape the NAb activity of serum 3.
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Cross-reactivity of sera from patients against AAV 
mutants isolated in HEK293 cells
A number of mutants isolated from patient serum had the ability to 
escape the NAb activity of their cognate serum as described above. 
Next, we analyzed the cross-reactivity of patient NAbs with mutants 
isolated against other patient sera. Some mutants isolated from one 
serum could also escape the NAb activity of the other two sera, such 
as AAV001-1, 11, 12, 14, 17, AAV002-9, 14, and AAV003-19 (Table 
1 and Supplementary Figure S2). These results indicate that it is 
possible to isolate AAV mutants that possess a generic ability to 
evade NAbs from multiple subjects. Other mutants had an ability to 
escape the NAbs from one but not another alternative patient serum 
such as AAV001-4, 5, 15, AAV002-15, and AAV003-7. Interestingly, 
most mutants isolated from serum 3 could only evade NAbs of 
Table 1 Characterization of AAV mutants isolated from HEK293 cells
HEK293 Virus titerb
Composition of 
capsidc
VP3  
composition
Serum 1 
Nab activityd
Serum 2 
Nab activity
Serum 3 
Nab activity
AAV001-1 -14a 2 2198989 8989 − − −
AAV001-4 -20 2 19898 898 − − +
AAV001-5 -11 2 21898 898 − − +
AAV001-7 -8 10 18 18 + + +
AAV001-11 -50 2 21898 898 − − −
AAV001-12 NC 0.5 218989 8989 − − −
AAV001-14 1 4 218989 8989 − − −
AAV001-15 NC 0.02 21898 898 − − +
AAV001-17 -14 8 21898 898 − − −
AAV002-1 -14 2 198989 8989 + + +
AAV002-3 -17 2 1989898 89898 + + +
AAV002-6 -10 4 189 189 + + +
AAV002-9 NC 0.2 198989 8989 − − −
AAV002-14 -4 4 12 12 − − −
AAV002-15 -6 2 289812 89812 + − +
AAV002-16 -4 4 2 2 + + +
AAV002-20 -8 2 189 189 + + +
AAV003-1 -20 4 2418 18 + + +
AAV003-3 -20 10 18418 18 + + +
AAV003-5 -11 10 818 18 + + +
AAV003-7 -9 4 12 12 + + +
AAV003-8 -20 4 18 18 + + +
AAV003-9 -11 6 28 28 + + +
AAV003-10 -20 6 2418 18 + + +
AAV003-11 -11 8 2418 18 + + +
AAV003-16 -11 2 2818 18 + + +
AAV003-17 -8 4 8 8 + + +
AAV003-18 -50 4 2418 18 + + +
AAV003-19 NC 0.5 818 18 − − −
AAV1 -5 2 1 1 + + +
AAV2 1 4 2 2 + + +
AAV2.5 1 2 2 with 5 mutations 2 with 5 mutations + + +
AAV4 -20 2 4 4 + + +
AAV6 -5 2 6 6 + + +
AAV8 -33 4 8 8 + − +
AAV9 -100 6 9 9 − − +
AAV, adeno-associated virus; NC, not comparable due to lower virus titer; PBS, phosphate-buffered saline.
aFold change when compared to AAV2 transduction, (−) indicates fold decrease. bVirus titer yield (107 particles/µl) in 1 ml of supernatant from one 10 cm plate from 
one transfection. cThe composition of capsid derived from wild-type AAV in the sequential order. dSerum neutralizing activity against AAV transduction when undiluted 
sera were incubated with AAV vectors. (−) indicates AAV transduction is >50% when compared to AAV incubation with PBS; (+) AAV transduction <50% of control 
group.
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serum 3 but could not evade NAbs from serum 1 or 2 (Table 1 and 
Supplementary Figure S2). These data suggest that AAV capsid 
NAb escape mutants isolated from individual serum may be differ-
ent from those from a traditional pooled sera approach.
In vivo transduction profile of AAV mutants isolated 
in HEK293 cells
To determine the tissue tropism of AAV mutants isolated in 
HEK293 in the presence of patient serum, 1 × 1011 particles of 
selected AAV vectors encoding the luc transgene were retro-
orbitally injected into 6-week-old female BALB/c mice. After 
1 week, in vivo images were captured. Consistent with the 
literature, AAV8 and 2 mainly transduced the liver, AAV4 trans-
duced the heart, AAV1 transduced both liver and heart, and 
AAV9 transduced almost every tissue (Supplementary Figure 
S3). Compared to parental AAV serotypes, all mutants except 
for AAV002-14 transduced the liver, but to a lesser extent than 
AAV8. Two weeks postinjection, tissue was harvested and lucif-
erase activity was analyzed. AAV003-7, a chimeric of AAV1 and 
2, had a similar muscle transduction to serotypes AAV4 and 
9, higher than parental serotypes (Supplementary Figure S3). 
Overall lower transduction was observed across different tis-
sues using chimeric mutants compared to parental serotypes. 
These results suggest that mutants with the ability to escape NAb 
Figure 1 Transduction efficiency of AAV mutants recovered from mouse skeletal muscle. 1 × 1010 particles of the AAV shuffled library virus incu-
bated with human serum 3 and administered via i.m. injection to 6-week-old female BALB/c mice. Three days postinjection, Ad dl309 was injected 
into the same muscle. (a) After 2 days, AAV mutant capsids were recovered from the injected muscle and sequenced. These mutant capsids were used 
to package the luc transgene. 1 × 109 particles of AAV/luc were administered via i.m. injection in both legs of 6-week-old female BALB/c mice (n = 2 
mice). One week post AAV application, (b) imaging was carried out and (c) the photon signal was measured and the average signal from all four legs 
was calculated. The exposure time for imaging was 10 seconds for AAV6, Mus3, and 12, and 5 minutes for other mutants and AAV serotypes. AAV, 
adeno-associated virus; i.m., intramuscular.
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should be further analyzed in vivo for maintenance of tissue-
specific transduction.
Isolation of AAV mutants from mouse skeletal muscle 
in the presence of human serum
As proof of principle, we successfully obtained chimeric capsid 
AAV mutants that evade NAb activity of human sera in HEK293 
cells. Although most of these mutants transduced cells efficiently 
in vitro, this may not translate into successful transduction in vivo. 
To develop tissue-tropic AAV mutants with NAb evasion ability, we 
directly injected a mixture of the AAV shuffling library and DMD 
patient 3 serum into the muscle of 6-week-old female BALB/c mice. 
Three days postinjection, Ad was injected into the same muscle to 
amplify the AAV genomes. Two days post Ad injection, muscle 
was collected for total DNA extraction. PCR was used to amplify 
mutant capsid sequences, and PCR products were subsequently 
cloned into the pXR2 backbone. Eight colonies were obtained and 
sequenced; every clone contained the C-terminus of the AAV8 VP3 
capsid except for Mus4 for which the C-terminus contained 10 aa 
residues from AAV6 (Figure 1a).
Transduction efficiencies of AAV mutants recovered 
from mouse skeletal muscle
To determine the relative muscle tropism of chimeric capsid 
AAV mutants isolated from mouse muscle, 1 × 109 particles 
of AAV mutants as well as parental AAV serotypes encoding 
the luc transgene were delivered via i.m. injection of 6-week-
old female BALB/c mice. One week postinjection, imaging was 
performed. As shown in Figure 1, AAV6 remained superior 
for muscle transduction, with a transduction efficiency order: 
AAV6>Mus12>Mus3>Mus11>AAV9=Mus4=Mus19=Mus24= 
AAV1>AAV2>AAV8>Mus14>Mus9.
To examine muscle transduction after systemic adminis-
tration, 1 × 1011 particles of AAV mutants as well as parental 
serotypes were injected via the retro-orbital vein into 6-week-
old female BALB/c mice. One week postinjection, imaging 
was performed. At 2 weeks postinjection, various tissues were 
collected for in vitro luc activity analysis. Consistent with 
prior reports, AAV9 was superior in transducing mouse tissue 
(Supplementary Figure S4). Among six mutants, Mus19 and 
24 were able to transduce the liver more efficiently than other 
mutants, with similar performance compared to parental AAV6, 
and lower efficiency than AAV8 or 9. Regarding muscle tropism, 
Mus11 was superior in transducing both heart and skeletal mus-
cles compared to other mutants. However, heart transduction of 
Mus11 was lower than that of AAV6, 8, and 9. Skeletal muscle 
transduction by Mus11 was higher than that of AAV6 but lower 
than that of AAV8 or 9. Lastly, Mus19 induced better skeletal 
muscle transduction than AAV6. These data indicate that high 
muscle transduction of mutants delivered via i.m. injection does 
not translate into high muscle tropism by systemic administra-
tion. These results are similar to the observation that AAV6, the 
Figure 2 NAb escape potential for AAV mutants derived from muscle. 1 × 109 particles of AAV/luc from mutants isolated from mouse muscle and 
wild serotypes were incubated with an equal volume of fivefold diluted patient serum 3 or PBS for 2 hours at 4 °C, then administered via i.m. injection 
to muscles of both legs in 6-week-old female BALB/c mice (n = 2). Three weeks post AAV application, mice were imaged for (a) luc expression. The 
photon signal was measured, and (b) the average signal for mice treated with human serum 3 or PBS was calculated for 4 legs. (c) The inhibition of 
human serum 3 on AAV transduction was analyzed by comparison of transgene expression in serum-treated mice over that of PBS-treated mice. The 
exposure time for imaging was 10 seconds for AAV6, Mus3, and 12, and 5 minutes for other mutants as well as AAV8 and 9. AAV, adeno-associated 
virus; i.m., intramuscular; NAb, neutralizing antibody; PBS, phosphate-buffered saline.
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serotype superior for muscle transduction following i.m. injec-
tion, performs worse than AAV8 or 9 in transducing muscle 
after systemic application.
NAb escaping ability of muscle-derived AAV mutants 
in vivo
In vitro data showed that undiluted patient serum 3 inhibited 
transduction by parental AAV serotypes 1, 2, 4, 8, 9, and mutant 
AAV2.5 (Table 1 and Supplementary Figure S2). To determine 
whether the chimeric capsid AAV mutants isolated from muscle 
tissue could evade NAb activity from serum and successfully 
transduce mouse muscle, we delivered 1 × 109 particles of AAV 
mutants or parental serotypes encoding the luc transgene mixed 
with fivefold diluted serum 3 or phosphate-buffered saline (PBS) 
via i.m. injection to 6-week-old female BALB/c mice. One week 
postinjection, imaging was performed. Serum 3 inhibited muscle 
transduction >50% for all parental serotypes and mutant AAV2.5 
except for AAV8, and also inhibited Mus12. However, no suppres-
sion of luc expression was observed in muscle injected with Mus3, 
4, 11, 19, or 24 (Figure 2).
Cross-reactive NAb escaping ability of muscle-derived 
AAV mutants
In vitro experiments demonstrated that the mutants isolated 
from serum 3 had a higher capacity to escape NAb activity from 
serum 3 than from sera 1 and 2. To determine whether muscle-
isolated mutants that escaped serum 3 NAbs could also evade 
NAbs from sera 1 and 2, we delivered 1 × 109 particles of AAV 
mutants or parental serotypes encoding the luc transgene mixed 
with fivefold diluted serum 1 or 2 or PBS via i.m. injection to 
6-week-old female BALB/c mice. As shown in Figure 3, strong 
inhibition of AAV6 transduction in the presence of sera 1 or 2 
Figure 3 Cross-reactivity of NAbs on AAV mutants isolated from muscle. 1 × 109 particles of AAV/luc mutants isolated from mouse muscle and 
wild serotypes were incubated with an equal volume of fivefold diluted patient serum 1, 2, or PBS for 2 hours at 4 °C, then the mixture of AAV/luc 
and serum was administered via i.m. injection into both legs of 6-week-old BALB/c mice (n = 2). (a) At 1 week post AAV administration, imaging was 
taken for luc expression. The average signal for legs in mice treated with (b) patient serum 1 or (d) 2 or PBS was calculated (b and d for serum 1 and 
2, respectively). The inhibition of human (c) serum 1 or (e) 2 on AAV transduction was analyzed by comparison of transgene expression in serum 
treated mice over that in PBS mice. The exposure time for imaging was 10 seconds for AAV6, Mus3, and 12, and 5 minutes for other mutants and 
AAV8 and 9. AAV, adeno-associated virus; i.m., intramuscular; NAb, neutralizing antibody; PBS, phosphate-buffered saline.
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was seen 1 week postinjection. Unlike serum 3, both sera 1 and 
2 suppressed AAV8 muscle transduction >50%; AAV9 muscle 
transduction was not inhibited (>50% of PBS group). Whereas 
the Mus12 mutant was inhibited by serum 3, sera 1 or 2 did 
not inhibit muscle transduction. Although serum 1 was able 
to inhibit muscle transduction from the other 5 Mus mutants 
>50%, serum 2 only inhibited muscle transduction from Mus3 
and 24, but not from Mus4, 11, and 19. These results indicate 
that some mutants isolated from serum 3 also possess NAb 
escaping ability toward other sera but that the efficiency of NAb 
escape varied across sera.
Elucidation of the capsid regions for mutants with 
NAb escape ability and muscle tropism
We successfully recovered eight mutants from mouse muscles 
in the presence of human serum, and the capsid sequence data 
showed an exclusivity of AAV8 capsid sequence in the C-terminus 
from aa residues 446 to the end. We wondered whether this VP 
region might play a role in NAb escape ability for the mutants. 
We therefore swapped the corresponding domains of AAV2 and 
AAV8, and subsequently carried out an in vitro NAb titer assay. 
It was demonstrated that the same dilution of serum 3 inhibited 
AAV2 and the AAV8/2 chimeric vector transduction by 50% at a 
128-fold dilution but inhibited AAV8 and AAV2/8 at a more con-
centrated 4-fold dilution (Figure 4). These results suggest that it 
is possible to identify VP regions responsible for NAb binding via 
selection of AAV mutants in the presence of NAbs.
As described above, six out of eight Mus mutants recovered 
from muscle in the presence of human serum showed higher 
muscle tropism than parental AAV2, and four mutants (Mus3, 11, 
19, and 24) contained a motif from the AAV6 capsid around aa 
residues 347 to 446 in VP1. To determine whether the motif from 
AAV6 capsid plays a role in muscle tropism, we made an AAV2 
mutant virus (AAV262) by swapping a capsid fragment of AAV6 
at aa residues 347 to 446 into the AAV2 capsid, and delivered 
1 × 109 particles via i.m. injection to 6-week-old female BALB/c 
mice. Compared to AAV2 muscle transduction, 3- to 10-fold 
higher transgene expression was achieved using the AAV262 vec-
tor. However, AAV262 muscle transduction remained sevenfold 
less efficient than AAV6 (Figure 5). This result suggests that aa 
residues 347 to 446 from AAV6 VP1 contribute to muscle tropism 
in recovered mutants. Thus, in this study, we are not only able 
to identify putative capsid motifs responsible for NAb binding, 
but also determine motifs important for tropism and enhanced 
muscle transduction by studying in vivo escape mutants.
Figure 4 The C-terminus of AAV2 VP3 is responsible for NAb bind-
ing. (a) A diagram of AAV mutants with swapped domains between 
the AAV2 and AAV8 capsids. (b) NAb titer analysis of AAV mutants with 
domain swapping. Patient 3 serum with twofold serial dilutions were 
incubated with AAV mutants and AAV2 or AAV8 at equal volumes of 
1 × 108 particles for 2 hours at 4 °C, then added to RC32 cells in the pres-
ence of Ad dl309 (MOI of 5). One day later, luc activity was measured, 
and transgene expression efficiency was calculated against transduction 
of AAV mixed with PBS only (control). AAV, adeno-associated virus; MOI, 
multiplicity of infection; NAb, neutralizing antibody; PBS, phosphate-
buffered saline.
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Figure 5 A capsid domain of AAV6 contributing to robust muscle tro-
pism. 1 × 109 particles of AAV/luc from mutant AAV262 and wt AAV2 or 6 
were administered via i.m. injection to muscles of both legs of 6-week-old 
female BALB/c mice. One week postinjection, imaging was taken and cal-
culated quantitatively. (a) Diagram of AAV262 mutant. (b) Imaging 1 week 
post AAV/luc vector i.m. administration. The exposure time was 1 minute 
for AAV2 and AAV262, and 10 seconds for AAV6. (c) Quantitation of luc 
imaging. (d) Fold increase of luc expression from AAV262 and AAV6 trans-
duction in muscles over that of the AAV2 vector. AAV, adeno-associated 
virus; i.m., intramuscular; PBS, phosphate-buffered saline.
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Figure 6 Phylogeny and structural models of AAV mutants. (a) Neighbor-joining phylogeny of the VP1 capsid sequence of NAb evading AAV 
mutants. Capsid aa sequences of AAVs were aligned using ClustalW, and the phylogeny was generated using a neighbor-joining algorithm and a 
Poisson correction to calculate aa distances. HEK293 isolates AAV001-1, AAV002-14, AAV003-19, and the skeletal muscle isolate Mus12 were selected 
for further structural modeling based on their distinct clades on the phylogenetic tree and functional ability to broadly escape NAbs. (b) Three-
dimensional structural models of select AAV NAb escape mutant that broadly escape NAbs. Three-dimensional surface models of capsid subunit 
trimer/threefold and the pentamer/fivefold symmetry axis regions of AAV NAb escape mutants isolated from 293 cells in vitro or recovered from 
mouse skeletal muscle in vivo. Amino acid residues derived from different AAV serotypes are highlighted as follows: purple (AAV1), blue (AAV2), 
hot pink (AAV6), green (AAV8), and brown (AAV9). Point mutations are highlighted in orange. Specific residues and point mutations are listed in 
Supplementary Figure S1. The surface model of the full capsid (60-mer) of the muscle isolate Mus12 is also shown with aa residues derived from 
AAV8 highlighted in green and residues derived from AAV9 colored brown. All structural models were visualized using PyMOL (http://www.pymol.
org/, The PyMOL Molecular Graphics System, Version 1.5.0.4; Schrödinger). AAV, adeno-associated virus; NAb, neutralizing antibody.
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DISCUSSION
The objective of this proof-of-principle study was to explore the 
possibility of isolating AAV mutants that evade NAbs and retain 
efficient tissue transduction to facilitate repeat administration in 
patients who were previously treated with AAV. We first isolated 
AAV mutants in the presence of sera from different human sub-
jects in vitro and demonstrated that these mutants possessed the 
capacity for evading NAb activity from different sera. Whereas 
some mutants had the generic ability to escape NAbs across dif-
ferent serum sources, others could escape NAbs from cognate 
serum far more efficiently than from other sera. Essentially all 
mutant capsids selected in vitro had reduced transduction in vivo 
compared to standard serotypes. However, in selecting tissue-spe-
cific AAV mutants with NAb evasion ability, we recovered eight 
mutants that escaped human serum to transduce mouse muscle. 
Six of the mutants initiated higher muscle transduction than most 
serotypes. Among the six mutants with high muscle tropism, five 
were better able to evade NAbs in cognate serum than any paren-
tal AAV serotype. Another had the ability to escape NAbs from 
other sera with efficiency varying by mutant and serum. Finally, 
based on our NAb escape mutant capsid composition data, we 
identified the domains responsible for NAb escape activity and 
muscle tropism.
AAV gene therapy has been successfully used for phase 1 
clinical trials in patients with vision and bleeding disorders.1–5 
Transgenic coagulation F.IX has been successfully delivered to 
the bloodstream after AAV vector delivery to the liver in patients 
with hemophilia B1,2. However, this treatment has only benefited 
a small set of patients, as more than 50% of people carry NAbs 
that inhibit AAV transduction. To evade AAV NAb activity, sev-
eral strategies have been tested to either protect AAV vectors 
from neutralization or to decrease NAb titers in the patient’s 
blood. Polymer (e.g., polyethylene glycol) has been used to coat 
the AAV surface and block NAb recognition.32–34 This approach is 
difficult to reproduce with respect to equal coating and has been 
suggested to change the AAV transduction profile. A second 
approach has used error-prone PCR or DNA shuffling to gen-
erate a library of AAV capsid variants to select for NAb escape 
mutants in the presence of NAbs in vitro.28–30,37 This approach has 
yielded novel capsids; however, it bears the potential limitation of 
generating capsids with unknown transduction efficiency in vivo. 
In the present study, we recovered escape mutants from HEK293 
cells in the presence of human NAb sera that had similarly com-
promised transduction in vivo. In animal models, several studies 
have found that separate serotypes of AAV show little or no NAb 
cross-reactivity; thus, it has been suggested to use other sero-
types to overcome NAb inhibition.9,13,24–27 While this strategy is 
logical, additional studies suggest that concern remains about the 
possibility of cross-reactivity in most humans which may not be 
predicted in animals.17 A finally attempted approach to resolve 
NAb inhibition has been rational mutation of the NAb bind-
ing domain on the AAV capsid surface.27 This strategy requires 
information about monoclonal antibody (mAb) epitopes and the 
structure of the AAV virion. While successful and informative, 
this approach is inherently limited due to polyclonal nature of 
human NAbs, and the difficulty in obtaining mAbs representing 
all generated NAbs.
In addition to vector modification, several clinical approaches 
have been employed such as plasmapheresis prior to vector 
delivery.21 Due to the relative inefficiency of each round of plas-
mapheresis and the fact that even low titers of NAbs (<1:5) can 
abrogate AAV transduction, this strategy is generally only suitable 
for patients with lower starting titers of AAV NAbs and requires 
multiple sessions. Similar to plasmapheresis, the use of balloon 
catheters in combination with a saline flush have shown efficacy 
for liver gene transduction in the presence of low to moderate 
NAb titers.40 More recently, the use of an anti-CD20 antibody 
(rituximab) to achieve B-cell depletion for 6–9 months has been 
reported. This approach is not directed at (antibody-producing) 
plasma cells and is effective in reducing AAV NAb in only a 
minority of subjects who have a NAb titer less than 1:1,000 (ref. 
22). A final clinical approach applies excessive empty AAV capsids 
as decoys for NAbs.23 Here, a major concern is that the addition 
of empty particles could increase the AAV capsid load, risking 
induction of capsid dose-related cytotoxic immune response and 
perhaps competing with full AAV particles for effective transduc-
tion.41 No standardization of processes leading to the generation 
of “empty particles” exists, and it has recently been reported that 
partially empty capsids (coproduced with vector) results in greater 
apparent liver inflammation than when using genome-containing 
AAV vectors only.42
With this backdrop, we have applied the strategy of directed 
evolution to develop novel AAV variants in the presence of 
human NAbs from AAV-treated patients.6,35,38,43 We successfully 
isolated several AAV mutants in the presence of sera from three 
patients when selected in vitro. Some of these chimeric capsids 
could escape the NAb activity from all three patients, while oth-
ers induced higher transduction in the presence of the cognate 
serum from which the evolutionary pressure was derived. Such 
results suggest that it is necessary to develop individual NAb 
escape mutants in the presence of serum from the specific subject, 
although it is possible (as we have also found) that some of AAV 
mutants isolated from one subject serum may confer generic NAb 
escape ability across other sera. Because the mechanism of vary-
ing AAV transduction efficiencies in different cells and tissues is 
unclear, and it is well known that the AAV transduction profile in 
vitro does not typically correlate in vivo, we have also determined 
that it is imperative to develop tissue-tropic AAV vectors with the 
ability to escape NAbs. Herein, we advanced the in vitro approach 
to in vivo selection in mouse muscle. Six mutants were isolated 
from mouse muscle that could evade serum NAbs from patient 
samples. The data clearly indicate the feasibility of developing 
NAb evasion mutants with enhanced AAV transduction efficiency 
but more importantly provide a roadmap for protein domains 
required for these functions in chimeric capsids. Additionally, 
the results obtained in this and our studies strongly suggest that 
selection of NAb escape AAV mutants should be performed in the 
presence of individual antiserum but not using pooled antisera 
(e.g., intravenous immunglobin). Pooled sera are collected from 
different population of human subjects. In this mixed sera, some 
subjects have no AAV NAb and others have different titers of NAb 
(as high as 1:1,000).17 When sera from these subjects are pooled 
together, the titer of AAV NAb actually is decreased due to dilu-
tion, and the NAb activity from some subjects may disappear due 
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to low NAb titer. Therefore mutants isolated against pooled anti-
sera may only be applied to subjects with high NAb titer.
Structural studies have demonstrated that there are nine vari-
able regions (VRs) on the AAV virion surface that are responsible 
for AAV serotype tropism and transduction as well as NAb recogni-
tion.44–47 For an individual subject, NAb activity will vary in strength 
to distinct serotypes. The capsid genomes of our AAV shuffled library 
are a mixture of AAV serotypes 1 through 9. Thus, Nab-binding sites 
from one but not another serotype may be present on the chime-
ric virion surface. Therefore, using the directed evolution/shuffling 
approach we can identify NAb binding domains by analyzing the 
mutant capsids that possess NAb escape abilities. We first carried 
out phylogenetic analysis of different isolates obtained from both in 
vitro and in vivo studies to assess the diversity of mutants obtained by 
directed evolution (Figure 6a). Consistent with functional data, we 
observed that the broad NAb evading clones, AAV001-1, AAV002-
14, and AAV003-19, are distinct isolates belonging to different 
clades. It is interesting to note that the broad NAb escaping muscle 
isolate, Mus12, is phylogenetically similar to AAV001-1, despite 
being recovered from skeletal muscle tissue in vivo. Furthermore, 
AAV002-14 is located in the same clade containing AAV1/AAV6. 
Overall from different muscle isolates, we noted that every escape 
mutant contained AAV8-derived capsid sequence at the C-terminus. 
Consistent with this observation, AAV8 had a superior ability to 
escape NAbs than any other serotype in the presence of patient 3 
serum both in vitro and in vivo. Findings based on swapping the 
C-terminus of AAV2 and AAV8 further supported that NAb bind-
ing sites from patient 3 serum were localized to the C-terminus of 
the AAV2 (but not AAV8) capsid. Therefore, modification of the 
AAV2 capsid C-terminus can evade NAb inhibition of AAV trans-
duction. It is interesting to note that Mus3 and 12 were most success-
ful at inducing muscle transduction after direct injection among the 
six mutants with high muscle tropism; however, their NAb evasion 
abilities varied dramatically: Mus3 was able to escape its cognate 
serum NAb but not sera from the other two patients, whereas Mus12 
could only evade NAb activity of sera from other patient sera but not 
from patient 3. The sequence alignment between the two mutants 
revealed AAV8 sequences downstream of residue 448, and that both 
capsids had AAV9 sequences upstream of residue 317 containing 
variable point mutations. However, each had aa insertions from a 
wide variety of parental serotypes located between residues 318–447 
(Mus3 has AAV9 and AAV6, Mus12 has AAV8). Other observed 
differences between the Mus3 and 12 mutants are located in residues 
327, 329, and 331, which have previously been shown to be located 
near the fivefold pore surface, a region that has not been identified as 
a determinant of antigenic reactivity in previous studies.47
It is well known that AAV vectors from different serotypes 
display various muscle tropisms: AAV1 or AAV6, which differ by 
six aa residues, induce the best muscle transduction in mice.48,49 
Previous studies have shown that chimeric vectors with aa resi-
dues 350 to 430 of AAV2 VP1 induce much higher muscle trans-
duction when substituted with the corresponding sequence from 
AAV1.50,51 Consistent with the chimeric vector study, 4 mutants 
(Mus3, 11, 19, and 24) contained aa residues 347 to 446 of VP1 
(containing VRIII) derived from AAV1/6, and synthetic AAV2 
mutants specifically designed to swap corresponding sequences 
from AAV6 led to higher muscle transduction. Importantly, the 
approach used here not only identified chimeric mutants with 
NAb evasion, but also provided an effective platform to identify 
motifs responsible for tissue tropism.
Finally, we carried out structural modeling of each representa-
tive broad NAb escaping mutant to determine whether structure–
function correlation can be established. Specifically, we modeled 
trimers and pentamers of different VP subunit sequences derived 
from the clones AAV001-1, AAV002-14, and AAV003-19 as well 
as the Mus12 isolate (Figure 6b). We noted that the region most 
varied from the AAV8 capsid sequence is between aa residues 217 
and 316. This prominent surface domain contains VR I and has 
been implicated in earlier antigenicity studies.31 Furthermore, it 
is interesting to note that AAV001-1, which belongs to the same 
clade as Mus12 and AAV003-19, also contains the same region, 
albeit with fewer aa residues (233–315). These results suggest that 
it is possible to identify single immunodominant epitopes on the 
AAV capsid that can be engineered to mediate NAb evasion. In 
particular, AAV8 VR I appears particularly suitable for such appli-
cations without adversely affecting transduction efficiency.
The current study has certain limitations. For instance, we 
only selected AAV mutants in muscle tissue in the presence of 
human serum and only generated 30 unique clones for sequenc-
ing, which may be due to the different muscle fibers transduced 
from AAV library virus and Ad. Six out of 8 available mutant cap-
sids induced higher muscle transduction than AAV serotypes 1, 
2, 8, or 9, but all were slightly reduced compared to the superior 
muscle transduction of AAV6. Interestingly, most mutants induced 
higher transgene expression in muscle than AAV6 in the presence 
of patient NAbs. These results strongly support the feasibility of 
selection of AAV NAb escape mutants in the presence of NAb. 
By performing additional rounds of selection in the presence of 
human serum, perhaps we could have increased the likelihood of 
isolating a mutant with both NAb evasion and muscle transduction 
similar to AAV6. Another arguable limitation of this study is that 
the mutants recovered from muscle had lower muscular transduc-
tion than AAV9 upon systemic administration, although most dis-
played high muscle transduction after i.m. injection. Most likely, 
these mutants do not have high vascular permeability to transduce 
muscle as compared to AAV9. Maybe a better strategy to test in 
future studies would be to isolate AAV mutants from muscles after 
systemic administration of the AAV library and human serum as 
our results clearly demonstrate that each parameter in the selection 
process greatly influences chimeric capsid selection.
In summary, we have successfully recovered AAV mutants 
in vitro and from mouse muscle after pairing an AAV shuffled 
library with NAb-containing human serum. Although it is pos-
sible to obtain AAV mutants that evade NAb activity from differ-
ent subjects, we found that mutants isolated from specific patients 
are better at evading cognate serum-based NAbs than NAbs from 
others. Most importantly, the isolated mutants provide impor-
tant information for identifying both NAb binding domains on 
the AAV virion surface and identifying unique motifs confer-
ring muscle tissue tropism. These results establish a platform to 
allow us to generate a panel of AAV mutants isolated from differ-
ent patient sera, and these mutants will be tested for NAb evasion 
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capacity in patients involved in clinical trial. If no mutants are able 
to escape NAb from a specific patient, it is necessary to develop 
patient-specific mutants in the presence of cognate serum.
MATERIALS AND METHODS
Cell lines. HEK293 cells and RC32 cells (HeLa cells with stable AAV2 
rep expression) were maintained at 37 °C in 5% CO2 in Dulbecco’s 
modified Eagle’s medium with 10% fetal bovine serum and 10% 
penicillin–streptomycin.
Serum samples. Sera were collected from three DMD patients in our phase 
1 clinical trial at day 100 after i.m. injection of AAV2.5/mini-dystrophin 
vector and stored at −80 °C (ref. 6).
AAV virus production. A three plasmid transfection method was used to 
produce AAV vector, described previously.52 Briefly, AAV transgene plas-
mid pTR/CBA-luc, AAV helper plasmid, and Ad helper plasmid pXX6-
80 were cotransfected into HEK293 cells. Sixty hours posttransfection, 
HEK293 cells were collected and lysed. Supernatant was subjected to CsCl 
gradient ultra-centrifugation. Fractions containing AAV were collected 
and tittered by dot-blot.
NAb escaping AAV mutants screen in vitro. 2 × 105 HEK293 cells were 
seeded in a six-well plate at the time of the experiment. 2 × 109 particles 
of AAV capsid shuffling library in 10 μl PBS was incubated with 10 μl of 
undiluted patient serum for 2 hours at 4 °C. AAV/serum mixtures were 
applied to cells with the addition of Ad dl309 at a multiplicity of infec-
tion (MOI) of 5. Forty-eight hours posttreatment, cells were harvested 
and subjected to three freeze/thaw cycles. Lysates were centrifuged at 
2,000 rpm for 10 minutes to remove cell debris, and supernatant was 
used to repeat the process for three more cycles to amplify virus in the 
absence of patient serum. After the fourth cycle, Hirt DNA was extracted 
from HEK293 cells, and AAV mutant capsids were amplified by PCR with 
the following primers: F1 5′-CAACTCCATCACTAGGGGTTC and R1 
5′-CATGGGAAAGGTGCCAGA, which are localized at the AAV2 rep 
and AAV2 ITR, respectively. PCR using PfuUltra High-Fidelity DNA poly-
merase (Agilent Technologies, Santa Clara, CA) was conducted with the 
following conditions: 94 °C 30 seconds, 53 °C 30 seconds, 72 °C 3 minutes 
for 35 cycles. PCR products were digested with SwaI and XbaI and ligated 
into pXR2 digested with the same endonucleases. Clones were sequenced 
by the UNC-CH Genome Analysis Facility, and capsid sequence alignment 
was analyzed with VectorNTI (Invitrogen, Grand Island, NY).
Hirt DNA purification. Low-molecular-weight DNA was extracted from 
HEK293 cells as described previously.53 Briefly, HEK293 cell pellets were 
resuspended in 728 μl of Hirt buffer (20 mmol/l Tris–HCl, 20 mmol/l 
EDTA, pH 8.0) and lysed with the addition of 46 μl of 10% sodium dodecyl 
sulfate. 218 μl of 5 mol/l NaCl was added to the cell lysate solution and 
incubated for 1 hour on ice. Lysate was centrifuged at 15K rpm at 4 °C 
for 30 minutes. Supernatant was collected, and DNA was extracted with 
phenol/chloroform. DNA was precipitated with isopropranol, and resus-
pended in 50 μl TE buffer (10 mmol/l Tris–HCl, 1 mmol/l EDTA, pH 8.0) 
containing 100 μg/ml of DNase-free RNase.
In vitro transduction analysis. 1 × 105 293 cells were seeded in a 48-well plate 
for 2 hours. 1 × 108 particles of AAV/luc was added. Forty-eight hours postin-
fection, cells were lysed using Passive Lysis Buffer (Promega, Durham, NC). 
Cell lysate was transferred to a 96-well plate to measure luciferase activity 
with a Wallac1420 Victor2 microplate reader. For inhibition assay of trans-
gene expression in the presence of serum, 1 × 108 particles of AAV/luc in 10 
μl PBS were incubated with 10 μl serum for 2 hours at 4 °C, then added to 
HEK293 cells. Luciferase activity was measured 24 hours post-AAV infection.
NAb analyses. NAb analyses were performed as described previously with 
slight modification.17,27 Sera were serially diluted twofold with PBS. RC32 
cells were seeded in 300 μl cell media in a 48-well plate for 3 to 4 hours. 
1 × 108 particles of AAV/luc was incubated with each serum dilution in PBS 
for 2 hours at 4 °C in a total volume of 25 μl. AAV/sera mixtures were 
added to cells in a final volume of 125 μl, which contained 4 × 106 particles 
of Ad dl309. Cells with AAV/sera mixtures were incubated for 24 hours at 
37 °C. NAb titers were defined as the highest dilution for which luciferase 
activity was 50% less than controls (no sera).
NAb escaping AAV mutants isolated from mouse muscles. 1 × 1010 particles 
of the AAV capsid shuffling library virus in 50 μl PBS were mixed with 50 μl 
undiluted serum from patient 3 for 2 hours at 4 °C. The AAV/serum mixture 
was delivered via i.m. injection into the hind leg muscle of 6-week-old female 
BALB/c mice. Three days posttreatment, Ad virus dl309 was delivered via 
i.m. injection into the same muscle at MOI of 107 to amplify AAV genomes 
in vivo (Supplementary Figure S5). Muscle was collected 2 days post Ad 
administration, and total DNA was extracted using Qiagen Kit (Qiagen, 
Valencia, CA). PCR was carried out for amplification of AAV mutant capsids, 
as done above, using muscle DNA as template. PCR products were cloned 
into a pXR2 backbone. Colonies were sequenced and used to generate AAV/
luc mutant vectors. Housing and handling of mice was carried out in com-
pliance with the National Institutes of Health guidelines and an Institutional 
Animal Care and Use Committee approved protocol at UNC-CH.
Characterization of AAV mutants in mice. Six-week-old female BALB/c 
mice received 1 × 1011 particles of AAV/luc via retro-orbital injection. 
Luciferase expression was imaged 1 week postinjection using a Xenogen 
IVIS Lumina (Caliper Lifesciences, Waltham, MA) following i.p. injec-
tion of d-luciferin substrate at 120 mg/kg (Nanolight Pinetop, AZ). 
Bioluminescent images were analyzed using Living Image (PerkinElmer, 
Waltham, MA). For muscle transduction, 1 × 109 particles of AAV/luc were 
injected into the gastrocnemius of 6-week-old female BALB/c mice. Mice 
were imaged at the indicated time points.
Quantitation of luciferase expression in tissues. Animals utilized for imaging 
studies were sacrificed 2 weeks post AAV injection, and the following organs 
were collected: liver, spleen, kidney, heart, lung, skeletal muscle (gastrocne-
mius), and brain. Tissue was minced and homogenized in passive lysis buffer. 
Tissue lysates were centrifuged at 10K rpm for 5 minutes to remove cellular 
debris. Supernatant was transferred to 96-well plates for luciferase activity 
analysis as described above. Total protein concentration in tissue lysates were 
measured using the Bradford assay (BioRad Laboratories, Philadelphia, PA).
AAV mutant capsid cloning. AAV capsid swap cassettes were generated 
by PCR with primers listed in Supplementary Table S1. PCR products 
were ligated into the pXR2 backbone. To generate the pXR-262 clone, we 
first made the construct pXR-62. To generate pXR-62, we obtained a PCR 
product with primers F/R2-262 using pXR6 as a template and a PCR prod-
uct with primers F3-262/R using pXR2 as a template. Both PCR products 
were digested with SalI and NotI and ligated into pXR2 digested with the 
same endonucleases. Next, to generate pXR-262, we obtained a PCR prod-
uct with primers F2-262/R using pXR-62 as a template and a PCR prod-
uct with primers F/R1-262 using pXR2 as a template. Both PCR products 
were digested with SalI and NotI and ligated into pXR2 digested with the 
same endonucleases. To generate clone pXR-2/8, we obtained a PCR prod-
uct with primers F/R1-2/8 using pXR2 as a template and a PCR product 
with primers F2-2/8/R using pXR8 as a template. Both PCR products were 
digested with SalI and NotI and ligated into pXR2 digested with the same 
endonucleases. To generate clone pXR-8/2, we obtained PCR products 
with primers F3-262/R using pXR2 as a template and a PCR product using 
F/R2-2/8 using pXR8 as template. Both PCR products were digested with 
SalI and NotI and ligated into pXR2 digested with the same endonucleases. 
Colonies were verified by DNA sequencing.
Molecular modeling. Structural homology models of the AAV capsid 
mutants were obtained using the SWISS-MODEL online server (http://
swissmodel.expasy.org/),54 with the crystal structure of AAV8 VP3 (PDB 
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ID 2QA0) serving as a template. Structure-based alignment was generated 
using the secondary structure matching application in the WinCoot soft-
ware,55–57 with the AAV4 VP3 (PDB ID 3NG9) monomer being used as a 
template. The threefold and fivefold symmetry axes/VP3 trimers and pen-
tamers and the whole capsid were generated using the oligomer generator 
utility in VIPERdb (http://viperdb.scripps.edu/oligomer_multi.php)58 and 
visualized using the PyMOL Molecular Graphics System (Schrödinger).
Phylogenetic analysis. The entire capsid aa sequences of different AAV 
isolates were aligned using ClustalW,59 and phylogenetic trees were gener-
ated with the MEGAv5.05 software package.60 Computational algorithms 
including maximum likelihood, neighbor joining, minimum evolution, 
and maximum parsimony were used. The phylogeny was produced using 
the neighbor-joining algorithm, and aa distances were calculated using 
a Poisson correction. Statistical testing was done by bootstrapping with 
1,000 replicates to test the confidence of the phylogenetic analysis.
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Figure S3. Transduction profile in vivo for NAb escape mutants iso-
lated from HEK293 cells.
Figure S4. Transduction profile in vivo for NAb escape mutants iso-
lated from muscles with systemic administration.
Figure S5. AAV genome copy number in mouse muscle.
Table S1. List of primers
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